X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (755) 755
male (476) 476
index medicus (453) 453
pyrimidinones - pharmacokinetics (435) 435
lopinavir (375) 375
female (360) 360
pharmacology & pharmacy (325) 325
adult (316) 316
animals (310) 310
pyrimidinones - pharmacology (298) 298
pyrimidinones - administration & dosage (280) 280
pyrimidinones - therapeutic use (277) 277
hiv infections - drug therapy (253) 253
middle aged (215) 215
pharmacokinetics (206) 206
ritonavir (175) 175
infectious diseases (171) 171
pyrimidinones - chemistry (170) 170
pyrimidinones - adverse effects (153) 153
rats (150) 150
pyrimidinones - blood (149) 149
ritonavir - pharmacokinetics (141) 141
chemistry, medicinal (139) 139
ritonavir - administration & dosage (134) 134
ritonavir - therapeutic use (131) 131
hiv protease inhibitors - pharmacokinetics (130) 130
drug therapy, combination (126) 126
mice (121) 121
hiv (120) 120
protease inhibitors (110) 110
administration, oral (108) 108
dose-response relationship, drug (106) 106
drug interactions (106) 106
structure-activity relationship (105) 105
aged (104) 104
hiv protease inhibitors - therapeutic use (101) 101
hiv protease inhibitors - administration & dosage (98) 98
immunology (98) 98
pyrimidinones - chemical synthesis (93) 93
treatment outcome (92) 92
antiviral agents (84) 84
anti-hiv agents - pharmacokinetics (83) 83
lopinavir/ritonavir (83) 83
area under curve (81) 81
chemistry, organic (80) 80
oncology (78) 78
therapy (78) 78
hiv infections - virology (76) 76
drug administration schedule (74) 74
virology (74) 74
microbiology (72) 72
drug therapy (71) 71
antiretroviral therapy (70) 70
ritonavir - adverse effects (70) 70
research (67) 67
anti-hiv agents - therapeutic use (66) 66
analysis (65) 65
hiv-1 - drug effects (65) 65
viral load (62) 62
anti-hiv agents - administration & dosage (61) 61
article (61) 61
biological availability (61) 61
drug combinations (61) 61
ritonavir - blood (60) 60
hiv protease inhibitors - adverse effects (58) 58
rats, sprague-dawley (58) 58
adolescent (57) 57
cell line, tumor (57) 57
hiv protease inhibitors - blood (57) 57
safety (57) 57
mutation (56) 56
pyrimidinones - metabolism (56) 56
hiv-1 (55) 55
metabolism (55) 55
molecular structure (53) 53
dogs (52) 52
antiretroviral therapy, highly active (51) 51
cancer (51) 51
combination (51) 51
biochemistry & molecular biology (50) 50
hiv infections - blood (50) 50
in-vitro (50) 50
hiv protease inhibitors - pharmacology (49) 49
ritonavir - pharmacology (48) 48
dosage and administration (47) 47
health aspects (47) 47
resistance (47) 47
chromatography, high pressure liquid (46) 46
indinavir (46) 46
protease inhibitor (46) 46
saquinavir (46) 46
young adult (46) 46
melanoma (45) 45
human-immunodeficiency-virus (43) 43
pharmacology (43) 43
time factors (42) 42
care and treatment (40) 40
hiv infection (40) 40
anti-hiv agents (39) 39
half-life (39) 39
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (913) 913
German (8) 8
Hungarian (3) 3
Spanish (3) 3
Chinese (2) 2
French (2) 2
Japanese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy
Journal Article
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination... 
trametinib | melanoma | durable outcomes | BRAF | metastatic | dabrafenib | MULTICENTER | OPEN-LABEL | COMBINATION | TRIAL | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | POOLED ANALYSIS | NIVOLUMAB | IPILIMUMAB | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Original
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2007, Volume 46, Issue 11, pp. 941 - 952
Objective: To characterise the interactions between tacrolimus and antiretroviral drug combinations in hepatitis C virus-HIV co-infected patients who had... 
Antiretrovirals | HIV infections | Tacrolimus | Ritonavir | Lopinavir | Nelfinavir | Liver transplant | Hepatitis C | Efavirenz | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Ritonavir, pharmacokinetics | Efavirenz, pharmacokinetics | Antiretrovirals, pharmacokinetics | Tacrolimus, pharmacokinetics | Lopinavir, pharmacokinetics | Nelfinavir, pharmacokinetics | REVERSE-TRANSCRIPTASE INHIBITORS | KIDNEY-TRANSPLANTATION | PROTEASE-INHIBITOR | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | HUMAN-IMMUNODEFICIENCY-VIRUS | CLINICAL PHARMACOKINETICS | DRUG-DRUG INTERACTIONS | CONSENSUS DOCUMENT | ORGAN-TRANSPLANTATION | NELFINAVIR | Hepatitis C - therapy | Liver Transplantation | Area Under Curve | Humans | Middle Aged | Half-Life | Male | HIV - drug effects | Dose-Response Relationship, Drug | Benzoxazines - pharmacokinetics | Ritonavir - therapeutic use | Adult | Benzoxazines - blood | Female | Hepatitis C - complications | Nelfinavir - therapeutic use | Tacrolimus - blood | Ritonavir - blood | Pyrimidinones - therapeutic use | CD4 Lymphocyte Count | Graft Rejection - diagnosis | Tacrolimus - pharmacokinetics | Nelfinavir - blood | Benzoxazines - therapeutic use | Antiretroviral Therapy, Highly Active | Tacrolimus - therapeutic use | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Pyrimidinones - blood | HIV Infections - complications | HIV Infections - therapy | Aged | Nelfinavir - pharmacokinetics | Viral Load - methods
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2008, Volume 48, Issue 5, pp. 553 - 562
A total of 71 HIV‐negative healthy adults were randomized to 1 of 6 regimens to receive lopinavir/ritonavir tablets 400/100 mg twice daily (bid) or 800/200 mg... 
pharmacokinetics | lopinavir | Acid‐reducing agents | atazanavir | ritonavir | Atazanavir | Pharmacokinetics | Acid-reducing agents | Ritonavir | Lopinavir | acid-reducing agents | EFFICACY | VALIDATION | PHARMACOLOGY & PHARMACY | CLINICAL PHARMACOKINETICS | PROTEASE INHIBITORS | Area Under Curve | Ranitidine - pharmacokinetics | Humans | Middle Aged | Pyridines - pharmacokinetics | Biological Availability | Male | Anti-HIV Agents - administration & dosage | Anti-Ulcer Agents - pharmacokinetics | Dose-Response Relationship, Drug | Histamine H2 Antagonists - administration & dosage | Drug Interactions | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Adult | Female | Ranitidine - adverse effects | Anti-HIV Agents - blood | HIV Protease Inhibitors - blood | Pyridines - administration & dosage | Oligopeptides - blood | Ritonavir - administration & dosage | Ritonavir - blood | Oligopeptides - pharmacokinetics | Omeprazole - administration & dosage | Anti-Ulcer Agents - adverse effects | Histamine H2 Antagonists - adverse effects | Omeprazole - adverse effects | Omeprazole - pharmacokinetics | HIV Protease Inhibitors - administration & dosage | Histamine H2 Antagonists - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Pyrimidinones - blood | Anti-HIV Agents - pharmacokinetics | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Ranitidine - administration & dosage | Antiviral agents | Dosage and administration | Research | Drug interactions | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
CELL LUNG-CANCER | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | EFFICACY | PATHWAY | SAFETY | KINASE | RESISTANCE | DOSE-ESCALATION TRIAL | RAF INHIBITORS | IMPROVED SURVIVAL | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 08/2010, Volume 54, Issue 4, pp. 381 - 388
OBJECTIVE:Reduced lopinavir concentrations have been demonstrated with use of the capsule formulation during the third trimester of pregnancy. This study... 
pharmacokinetics | HIV | lopinavir | pregnancy | mother-to-child transmission | INFECTIOUS DISEASES | IMMUNOLOGY | ANTIRETROVIRALS | WOMEN | INHIBITOR-EXPERIENCED PATIENTS | CAPSULE | EXPOSURE | RITONAVIR
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 05/2009, Volume 53, Issue 5, pp. 1937 - 1943
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
IN-VITRO | HIV | DIDANOSINE | CARBOVIR TRIPHOSPHATE | REVERSE-TRANSCRIPTASE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | P-GLYCOPROTEIN EXPRESSION | LOPINAVIR/RITONAVIR | BLOOD MONONUCLEAR-CELLS | PROTEASE INHIBITORS | MASS-SPECTROMETRY | Lamivudine - administration & dosage | Area Under Curve | Humans | Middle Aged | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | Drug Therapy, Combination | Dideoxynucleosides - administration & dosage | Adenine - analogs & derivatives | Cross-Sectional Studies | Ritonavir - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Lopinavir | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | Lamivudine - pharmacokinetics | Adenine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Dideoxynucleosides - pharmacokinetics | Organophosphonates - administration & dosage | Pilot Projects | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | Longitudinal Studies | Index Medicus | Pharmacology
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2015, Volume 75, Issue 1, pp. 183 - 189
To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.Eligibility criteria... 
Medicine & Public Health | MEK Inhibitor | Afuresertib | Oncology | Cancer Research | Pharmacology/Toxicology | Combination therapy | AKT Inhibitor | Trametinib | MEK inhibitor | AKT inhibitor | MELANOMA | ONCOLOGY | PATHWAY | MUTATION | PHARMACOLOGY & PHARMACY | HUMAN CANCER | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Thiophenes - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Early Termination of Clinical Trials | Pyridones - administration & dosage | Multiple Myeloma - drug therapy | Neoplasms - blood | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Multiple Myeloma - enzymology | Pyrazoles - pharmacokinetics | Multiple Myeloma - blood | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Pyridones - pharmacokinetics | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasms - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Pyrimidinones - pharmacokinetics | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Pyridones - therapeutic use | Pyrimidinones - administration & dosage | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Pyridones - adverse effects | Cohort Studies | Complications and side effects | Medical research | Care and treatment | Type 1 diabetes | Analysis | Gastrointestinal diseases | Multiple myeloma | Melanoma | Medicine, Experimental | Aspartate | Nausea | Tumors | Index Medicus
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2008, Volume 47, Issue 5, pp. 570 - 578
OBJECTIVES:This open-label, single-arm, pharmacokinetic (PK) study in HIV-seronegative volunteers evaluated the bioequivalence of rosuvastatin and... 
Organic anion transporting polypeptide 1B1 | SLCO1B1 | Rosuvastatin | Lopinavir/ritonavir | Pharmacokinetics | Interaction | lopinavir/ritonavir | INFECTIOUS DISEASES | HIV PROTEASE INHIBITORS | organic anion transporting polypeptide 1B1 | ANTIRETROVIRAL THERAPY | TRANSPLANT RECIPIENTS | HEPATIC-UPTAKE | IMMUNOLOGY | VIRUS (HIV)-INFECTED ADULTS | INDUCED RHABDOMYOLYSIS | ANION TRANSPORTING POLYPEPTIDE | CYCLOSPORINE-A | PERIPHERAL LIPODYSTROPHY | interaction | pharmacokinetics | rosuvastatin | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Fluorobenzenes - pharmacokinetics | Humans | Middle Aged | Male | Fluorobenzenes - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Drug Interactions | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Lipids - blood | Adult | Female | HIV Protease Inhibitors - adverse effects | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Lopinavir | Pyrimidinones - adverse effects | Rosuvastatin Calcium | HIV Protease Inhibitors - administration & dosage | Sulfonamides - pharmacokinetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Adolescent | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Fluorobenzenes - adverse effects | Pyrimidinones - administration & dosage | Sulfonamides - administration & dosage | Index Medicus | AIDS/HIV
Journal Article